Open an account

Assembly Biosciences

ASMB · NASDAQ

$21.19+$1.03 (+5.11%)TodayMarket closed ·
Prev close $20.16

About ASMB

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).

Employees
73
Headquarters
South San Francisco, California
Listed
Dec 17, 2010
Sector
Health Care
Industry
Biotechnology
Website
assemblybio.com

ASMB key statistics

Market cap
431.44M
Price-earnings ratio
19.76
Dividend yield
—
Average volume
280.81K
Volume
222.71K
Open price
$20.23
High today
$21.48
Low today
$20.07
52 Week high
$39.71
52 Week low
$19.94

Assembly Biosciences (ASMB) at a glance

Assembly Biosciences (ASMB) last traded at $21.19, with a market cap of 431.44M and a price-to-earnings ratio of 19.76.

Today the stock has traded between $20.07 and $21.48. The current price is 5.6% above the day's low and 1.3% below its high.

Volume so far is 222.71K shares, below the average of 280.81K shares a day.

Over the past year Assembly Biosciences has ranged from $19.94 to $39.71, and now sits 6% of the way up that range.

Assembly Biosciences met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.20 per share against an estimate of -$0.6596.

The average analyst price target is $53.04, 150.3% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $53.04
Low
$43.43
Now
$21.19
High
$65.10

ASMB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 80.5% on average.

  1. Q3 FY24: reported -$1.51 per share against an estimate of -$2.06
  2. Q4 FY24: reported -$1.57 per share against an estimate of -$2.08
  3. Q1 FY25: reported -$1.17 per share against an estimate of -$1.63
  4. Q2 FY25: reported -$1.33 per share against an estimate of -$1.39
  5. Q3 FY25: reported -$0.72 per share against an estimate of -$0.7902
  6. Q4 FY25: reported $2.48 per share against an estimate of -$0.663
  7. Q1 FY26: reported -$0.54 per share against an estimate of -$0.5814
  8. Q2 FY26: reported -$0.20 per share against an estimate of -$0.6596

ASMB news

  • Avi Kapoor

    Crude Oil Edges Higher; US Consumer Sentiment Falls In May

  • Vandana Singh

    Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes

  • Press releaseBusiness Wire

    Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

  • Forecasting The Future: 4 Analyst Projections For Assembly Biosciences

  • Rishabh Mishra

    4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Press releaseBusiness Wire

    Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics

Similar companies

Companies in the same industry as Assembly Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.